Author: GarcÃa-AzorÃn, David; Abildúa, MarÃa José Abenza; Aguirre, MarÃa Elena Erro; Fernández, Santiago Fernández; Moncó, Juan Carlos GarcÃa; Guijarro, Cristina; Platas, Montserrat González; Delgado, Fernando Romero; Andrés, José Miguel Láinez; Ezpeleta, David
Title: Neurological presentations of COVID-19: Findings from the Spanish society of neurology neuroCOVID-19 registry Cord-id: zg46xikf Document date: 2020_12_19
ID: zg46xikf
Snippet: OBJECTIVE: We report the findings from the Spanish Society of Neurology's NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), n
Document: OBJECTIVE: We report the findings from the Spanish Society of Neurology's NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache. The onset of symptoms differed within categories. Onset of anosmia occurred a mean (standard deviation) of 2.9 (2.5) days after the first general symptom, whereas neuromuscular symptoms appeared after 13.9 (10.1) days. Neurological symptoms were persistent in 33% of patients. General symptoms were present in 97.7% of patients, and results from general laboratory studies were abnormal in 99.4% of patients. Cerebrospinal fluid analysis findings were abnormal in 62.7% of the cases in which this test was performed (n = 51), but positive results for SARS-CoV-2 were only found in one case. CONCLUSIONS: The neurological manifestations of COVID-19 are diverse. Anosmia, myalgia, and headache occur earlier in the course of the disease. Altered mental status, neuromuscular symptoms, and stroke are associated with greater severity. COVID-19 must be incorporated into most clinical and radiological differential diagnoses. COVID-19 may cause persistent and disabling neurological symptoms.
Search related documents:
Co phrase search for related documents- abnormal coagulation and acute kidney injury: 1, 2, 3
- abnormal coagulation and liver enzyme: 1
- abnormal result and acute ards respiratory distress syndrome: 1
- ace receptor and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- ace receptor and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- ace receptor and liver enzyme: 1
- ace receptor and local protocol: 1, 2
- ace receptor sars spike protein and acute kidney injury: 1
- acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
- acute ards respiratory distress syndrome and local protocol: 1, 2, 3
- acute kidney injury and liver enzyme: 1, 2, 3
- acute kidney injury and local protocol: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date